id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9760 R34844 |
Bank (Carbamazepine) (Mixed indications), 2017 | Apgar < 7 at 1 minute | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.43 [0.19;30.63] C | 1/8 2/36 | 3 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9598 R33993 |
Artama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | 1-min Apgar <7 | 3rd trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.67 [0.32;1.42] C excluded (control group) |
36/904 9/154 | 45 | 904 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9599 R34005 |
Artama (Carbamazepine) (Controls unexposed, disease free), 2013 | 1-min Apgar <7 | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.04 [0.74;1.45] excluded (control group) |
36/904 27,939/689,482 | 27,975 | 904 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9600 R34017 |
Artama (Carbamazepine) (Controls unexposed, sick), 2013 | 1-min Apgar <7 | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.06 [0.70;1.61] | 36/904 69/1,708 | 105 | 904 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9640 R34297 |
Pennell (Carbamazepine), 2012 | Apgar score (at 1 minute < 7) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.55 [0.76;8.60] C | 9/91 4/97 | 13 | 91 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9615 R34172 |
Endo (Carbamazepine) (Controls unexposed, disease free), 2004 | Apgar score (<8 at 1min) | throughout pregnancy | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
0.71 [0.09;5.89] C excluded (control group) |
1/8 47/280 | 48 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9616 R34187 |
Endo (Carbamazepine) (Controls unexposed, sick), 2004 | Apgar score (<8 at 1min) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 0.23 [0.00;17.06] C | 1/8 0/1 | 1 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9740 R34696 |
Van der Pol (Carbamazepine) (Controls unexposed, disease free), 1991 | Apgar scores (1 minute <7) | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
1.00 [0.11;9.51] C excluded (control group) |
1/11 5/55 | 6 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9741 R34721 |
Van der Pol (Carbamazepine) (Controls unexposed, sick), 1991 | Apgar scores (1 minute <7) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.10 [0.12;37.12] C | 1/11 1/22 | 2 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 1.18 [0.80;1.73] | 124 | 1,022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Mixed indications; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine; 4: Carbamazepine) (Controls unexposed, sick; 5: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.5455 (by Egger's regression)
slope=0.0399 (0.2557); intercept=0.3963 (0.5833); t=0.6795; p=0.5455
excluded 9740, 9615, 9598, 9599